{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:16:32Z","timestamp":1792293392537,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112945","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:38:01Z","timestamp":1760398681000},"page":"112945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-5425","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Taybani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-606X","authenticated-orcid":false,"given":"Alice","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-9205","authenticated-orcid":false,"given":"Amar","family":"Tebaibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nan","family":"Anaforoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Lauand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraly","family":"Servera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112945_b0005","unstructured":"Federation. ID. IDF Diabetes Atlas, 11th ed. Brussels, Belgium; 2025."},{"issue":"11","key":"10.1016\/j.diabres.2025.112945_b0010","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 202A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care."},{"key":"10.1016\/j.diabres.2025.112945_b0015","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabet Care. 2025;48(Supplement_1):S181-S206."},{"issue":"12","key":"10.1016\/j.diabres.2025.112945_b0020","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","article-title":"Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes","volume":"34","author":"Riddle","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.112945_b0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2025.112945_b0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.14298","article-title":"Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: a retrospective UK cohort study","volume":"23","author":"Jude","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2025.112945_b0035","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2337\/dc19-0968","article-title":"The probability of A1C Goal attainment in patients with uncontrolled type 2 diabetes in a large integrated delivery system: a prediction model","volume":"43","author":"Pantalone","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.112945_b0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00125-019-05078-3","article-title":"Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)","volume":"63","author":"Aschner","year":"2020","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2025.112945_b0045","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4239\/wjd.v15.i5.828","article-title":"Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges","volume":"15","author":"Emad-Eldin","year":"2024","journal-title":"World J Diabetes"},{"issue":"7","key":"10.1016\/j.diabres.2025.112945_b0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1037\/a0040388","article-title":"Psychosocial factors in medication adherence and diabetes self-management: implications for research and practice","volume":"71","author":"Gonzalez","year":"2016","journal-title":"Am Psychol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112945_b0055","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s13300-019-0673-8","article-title":"Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes","volume":"10","author":"Taybani","year":"2019","journal-title":"Diabetes Ther"},{"issue":"4","key":"10.1016\/j.diabres.2025.112945_b0060","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13300-022-01222-2","article-title":"Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes","volume":"13","author":"Jude","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.112945_b0065","unstructured":"Sanofi. Suliqua summary of product characteristics; 2020. https:\/\/www. medicines.org.uk\/emc\/product\/9871\/smpc."},{"issue":"10","key":"10.1016\/j.diabres.2025.112945_b0070","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2337\/dc21-0393","article-title":"Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial","volume":"44","author":"Rosenstock","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2025.112945_b0075","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14822","article-title":"Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial","volume":"24","author":"Polonsky","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112945_b0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/dom.14354","article-title":"Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: design and baseline characteristics of the SoliMix randomized controlled trial","volume":"23","author":"McCrimmon","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112945_b0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.14844","article-title":"iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify real-world study","volume":"25","author":"McCrimmon","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2025.112945_b0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s13300-023-01373-w","article-title":"Use of iGlarLixi for the management of type 2 diabetes in japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study","volume":"14","author":"Miyoshi","year":"2023","journal-title":"Diabetes Ther"},{"issue":"9","key":"10.1016\/j.diabres.2025.112945_b0095","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1111\/dom.15724","article-title":"The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: the Soli-D randomized controlled trial","volume":"26","author":"Liu","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112945_b0100","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s13300-024-01582-x","article-title":"The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) randomised controlled trial-study design and protocol","volume":"15","author":"Novodvorsky","year":"2024","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.diabres.2025.112945_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102707","article-title":"Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: the SoliRam observational study","volume":"17","author":"Hassanein","year":"2023","journal-title":"Diabetes Metab Syndr"},{"issue":"11","key":"10.1016\/j.diabres.2025.112945_b0110","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s13300-024-01642-2","article-title":"Safety and effectiveness of concomitant iGlarLixi and SGLT-2i use in people with T2D during ramadan fasting: a SoliRam study sub-analysis","volume":"15","author":"Hassanein","year":"2024","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.diabres.2025.112945_b0115","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s13300-024-01610-w","article-title":"Expert opinion on optimising type 2 diabetes treatment using fixed-ratio combination of basal insulin and GLP-1 RA for treatment intensification and simplification","volume":"15","author":"Haluzik","year":"2024","journal-title":"Diabetes Ther"},{"issue":"23","key":"10.1016\/j.diabres.2025.112945_b0120","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2025.112945_b0125","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized","volume":"44","author":"Giugliano","year":"2021","journal-title":"Pragm Trial Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2025.112945_b0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12020-023-03547-9","article-title":"BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes","volume":"83","author":"Giugliano","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.diabres.2025.112945_b0135","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2337\/db24-782-P","article-title":"Insulin therapy de-intensification with iGlarLixi \u2013 the IDEAL randomized controlled trial","volume":"73","author":"Peter Novodvorsk\u00fd","year":"2024","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2025.112945_b0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13300-019-00735-7","article-title":"Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis","volume":"11","author":"Tabak","year":"2020","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.diabres.2025.112945_b0145","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/dom.14974","article-title":"iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: the SoliComplex real-world study","volume":"25","author":"Lajara","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2025.112945_b0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2337\/ds22-0064","article-title":"Initiation of iGlarLixi versus basal-bolus insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliComplex real-world study","volume":"36","author":"Pantalone","year":"2023","journal-title":"Diabetes Spectr"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:25:32Z","timestamp":1764080732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"alternative-id":["S0168822725009593"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112945","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112945"}}